ClinicalTrials.gg
Status unknownNCT05340530Updated Apr 22, 2022

To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects

A Phase 1 interventional study of The injectable TQD3606 and meropenem in Infections, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-22.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

TQD3606 is a fixed-dose combination of meropenem and avibatam. This study is a phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of TQD3606 injection in a single center, randomized, double-blind, placebo-controlled, single and multiple administration in healthy subjects, and to explore the excretion of TQD3606 in urine. To evaluate the tolerability and safety of injectable TQD3606 after single and multiple dosing in healthy subjects.

02

Conditions studied

  • Infections

Browse trials for

03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's planned enrollment of 56 is below the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Signed the before the test and fully understood the test content, process and possible adverse reactions;
  • 2 Able to complete the research according to the requirements of the test plan;
  • 3 Subjects aged between 18 and 55 (including 18 and 55);
  • 4 (BMI) ≥ 18 and ≤ 28kg/m2, with male weight ≥ 50 kg and female weight ≥ 45 kg;
  • 5 Health status: No mental disorders, no history of cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolic abnormalities;
  • 6 Subjects had no pregnancy plan and voluntarily used effective measures for at least 6 months from 2 weeks before self-medication to the last use of study medication.

Exclusion criteria

Exclusion Criteria:

  • 1 Previous neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemolymph system, liver and kidney dysfunction, endocrine system, musculoskeletal system disease or other diseases, and the investigator judged that the previous history may affect drug metabolism or safety;
  • 2 Known allergic history to meropenem or avitabtam, known history of anaphylactic shock to penicillin, cephalosporins, carbapenems and other β -lactam antibiotics or other severe allergic reactions (such as bullous epidermolysis atrophic dermatitis, exudative dermatitis);
  • 3 Allergic constitution, including allergy to food and other drugs;
  • 4 Persons with a history of epilepsy or central nervous system dysfunction;
  • 5 Those with definite chronic headache or chronic diarrhea in the past;
  • 6 Changes in or QT Corrected (QTc) > 450ms were considered by researchers;
  • 7 The rate was less than 50ml/min;
  • 8 Taking any prescription, over-the-counter, vitamin products or herbal medicine within 2 weeks prior to screening;
  • 9 Abnormal and clinically significant laboratory tests during screening period;
  • 10 Blood donation or significant blood loss within 3 months prior to taking the study drug (>450 ml);
  • 11 Participated in any drug clinical trials within 3 months prior to taking the study drug;
  • 12 Heavy smokers (5 cigarettes or more per day) within 3 months prior to screening;
  • 13 Have a history of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit =360mL beer or 45mL 40% spirits or 150mL wine);
  • 14 Urine drug test positive or have a history of drug abuse or drug use in the past five years;
  • 15 Unable to tolerate venipuncture blood collection or poor vascular condition;
  • 16 Have taken a special diet (including dragon fruit, mango, grapefruit, grapefruit juice and/or xanthine diet) within 2 weeks prior to the trial;
  • 17 Consuming chocolate, caffeinated coffee or tea within 48 hours before the trial;
  • 18 Have taken any alcoholic food or beverage within 48 hours prior to the test;
  • 19 The subject cannot complete the test due to personal reasons;
  • 20 Conditions considered unsuitable for inclusion by other researchers.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    The injectable TQD3606

    received a single dose of 0.75g TQD3606 for injection

    Drug: The injectable TQD3606

  • Active comparator
    The injectable TQD3606+ meropenem

    First, a single dose of 0.5g of meropenem for injection was administered for 0.5h intravenous infusion; after washout for at least 2 days, 0.75g of TQD3606 for injection was administered for 1h intravenous infusion; for at least 2 days of washout, 0.75g was administered A single dose of TQD3606 for injection was administered for 2 hours, and the elution time was at least 2 days. Finally, a single dose of 0.75 g of TQD3606 for injection was administered, and the duration of intravenous infusion was 3 hours.

    Drug: The injectable TQD3606 · Drug: meropenem

  • Active comparator
    The injectable TQD3606+ meropenem+ Avibactam Sodium

    According to the random table, they were divided into two groups, A and B, Group A was given 1.0g meropenem for injection (Mepin) in the first cycle, and 0.5g avibactam sodium for injection in the second cycle. The third cycle was given 1.5g TQD3606 for injection; group B was given 0.5g avibactam sodium for injection in the first cycle, 1.0g meropenem (Mepin) for injection in the second cycle, and 1.5g for injection in the third cycle TQD3606.

    Drug: The injectable TQD3606 · Drug: meropenem · Drug: Avibactam Sodium

  • Experimental
    The injectable TQD3606-1

    First, 0.75g TQD3606 for injection was administered multiple times (Dosing every 8 hours, 3 consecutive doses), and at least 2 days were washed out after the last dose; then 1.125g TQD3606 for injection was administered multiple times (Dosing every 12 hours, 2 consecutive doses) times), wash out at least 2 days after the last administration; finally, a single administration of 2.25 g of TQD3606 for injection (Dosing every 12 hours, once administered). Intravenous infusion for 3 hours.

    Drug: The injectable TQD3606

  • Placebo comparator
    The injectable TQD3606/ Placebo

    First, a single dose of 3.0g TQD3606 for injection/placebo was administered, intravenous infusion for 3hours, and washout for at least 3 days; then multiple doses of 3.0g TQD3606 for injection/placebo were administered (Dosing every 8 hours, 10 consecutive doses) , the intravenous infusion duration is 3hours.

    Drug: The injectable TQD3606 · Drug: Placebo

Interventions

  • DrugThe injectable TQD3606

    TQD3606 is a fixed-dose combination of meropenem and avibatam.

  • Meropenem is a carbapenem antibiotic

  • Avibactam is beta-lactamase inhibitor.

  • DrugPlacebo

    It is a placebo.

06

What researchers measure

Primary outcomes

  1. Maximum Concentration (Cmax)

    Maximum Concentration

    Time frame: 1 hour before administration,to 24 hours after administration.

  2. Area under the plasma concentration-time curve from initial dosing to 24 hours (AUC0-24)

    Area under the plasma concentration-time curve from initial dosing to 24 hours

    Time frame: 1 hour before administration,to 24 hours after administration.

Secondary outcomes

  1. Time to maximum concentration following drug administration (Tmax)

    Time to maximum concentration following drug administration

    Time frame: 1 hour before administration,to 24 hours after administration.

  2. Apparent terminal elimination half-life following drug administration (t1/2)

    Apparent terminal elimination half-life following drug administration

    Time frame: 1 hour before administration,to 24 hours after administration.

  3. Area under plasma concentration-time curve from first dosing to last measurable concentration point (AUC0-t)

    Area under plasma concentration-time curve from first dosing to last measurable concentration point

    Time frame: 1 hour before administration,to 24 hours after administration.

  4. The amount of drug excreted through urine 24 hours after administration (Ae0-24)

    The amount of drug excreted through urine 24 hours after administration

    Time frame: 1 hour before administration,to 24 hours after administration.

  5. Cumulative excretion rate of drugs through urine

    Cumulative excretion rate of drugs through urine

    Time frame: 1 hour before administration,to 24 hours after administration.

  6. The total clearance (CLt) The total clearance (CLt)

    The total clearance

    Time frame: 1 hour before administration,to 24 hours after administration.

  7. Renal clearance (CLr)

    Renal clearance

    Time frame: 1 hour before administration,to 24 hours after administration.

  8. Elimination rate constant(λz)

    Elimination rate constant

    Time frame: 1 hour before administration,to 24 hours after administration.

  9. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution

    Time frame: 1 hour before administration,to 24 hours after administration.

  10. Mean residence time (MRT)

    Mean residence time

    Time frame: 1 hour before administration,to 24 hours after administration.

  11. Valley concentration (Cmin,ss)

    Valley concentration

    Time frame: Within 60 minutes before 8th to 10th administration and 24 hours after 10th administration

  12. Accumulation index

    Accumulation index

    Time frame: Within 60 minutes before 8th to 10th administration and 24 hours after 10th administration

  13. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 24 hours after administration

  14. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Monitor the safety indicators of subjects during the trial

    Time frame: Baseline up to 24 hours after administration

  15. Body temperature

    Monitor the safety indicators of subjects during the trial

    Time frame: 1 hour before administration and 24 hours after administration

  16. Pulse

    Monitor the safety indicators of subjects during the trial

    Time frame: 1 hour before administration and 24 hours after administration

  17. Systolic and diastolic blood pressure

    Monitor the safety indicators of subjects during the trial

    Time frame: 1 hour before administration and 24 hours after administration

  18. Number of participants with abnormal laboratory test results

    Monitor the safety indicators of subjects during the trial

    Time frame: Baseline up to 24 hours after administration

07

Study locations

1 site
  • Affiliated Hospital of Changchun University of Traditional Chinese Medicine
    Changchun, Jilin 130103, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2022; primary completion for Dec 2023, 20 months later.

Of 51 industry-sponsored phase 1 interventional studies under Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's planned 20 months is above that.

Counting every sponsor, half of 78 studies reached it within 10 months; a quarter within 3 and three quarters within 20.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 22, 2022
StartEst.
Apr 2022
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Apr 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05340530
Responsible party
Sponsor
First posted
Apr 22, 2022
Start date
Apr 2022 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Apr 22, 2022

Study contacts

Haimiao Yang, Master
Contact
czfyyq728@163.com
0431-86177635

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion